The human Epstein-Barr virus (EBV) is a type of herpes virus that infects 90 percent of the world population. EBV can trigger unregulated cell proliferation and survival, and is associated with many human cancers including Burkitt's lymphoma. Yin will study how EBV contributes to cell survival and cell division. He will incorporate knowledge of protein engineering, chemistry and viral biology and use a unique computational algorithm to design a new therapy specific to an EBV protein that is difficult to target with conventional therapies due to its location in the cell. If successful, this study will establish a new technique for targeting transmembrane proteins involved in important signaling pathways in cancer cells that could translate into a broad range of novel anti-cancer therapeutics.
Hang (Hubert) Yin, Ph.D., assistant professor of chemistry and biochemistry and task force member of the Colorado Initiative in Molecular Biotechnology at the University of Colorado
Watch an interview with Dr. Hang (Hubert) Yin on YouTube:
Updated: May 12, 2010